Barrick Mining Corporation Stock Price, News & Analysis

Barrick (NYSE:B) announced that Helen Cai will become Senior Executive Vice President and Chief Financial Officer effective March 1, 2026, following the departure of Graham Shuttleworth after the company’s year-end results. Ms. Cai will work with Mr. Shuttleworth during a transition period. Ms. Cai has served on Barrick’s board since November 2021 and brings over two decades of finance and mining‑sector experience, CFA and CAIA designations, and prior roles at Goldman Sachs and CICC.

Cereno Scientific (NASDAQ First North: B) announced a peer-reviewed publication (Journal of Thrombosis and Haemostasis) on CS014, a novel HDAC inhibitor engineered to improve upon valproic acid by reducing hepatotoxic 4-ene metabolite formation while preserving HDAC activity. The manuscript reports potent antithrombotic effects across small artery, large artery and large vein models achieved at doses that preserve normal coagulation and bleeding time. Cereno also reported positive Phase I safety and tolerability at exposures predicted to support efficacy and said it is preparing for Phase II with initial focus on idiopathic pulmonary fibrosis.

Hexagon US Federal (B) announced leadership transitions to support operational execution and mission delivery. On January 2, 2026, Elliott Ferguson was appointed President after serving as VP of Geospatial Solutions and being named Chief Operating Officer in 2024; Ferguson will focus on strategic execution, customer delivery and long-term growth. The company also named Phil Chandler VP of Business Operations, Victoria Privett VP of Corporate Services, Greta Brant Director of Contracts and Marc Langlois Director of Sales.

The appointments aim to position Hexagon US Federal to continue delivering solutions amid a potential Octave spinoff from Hexagon AB slated for the first half of 2026, with Octave focused on software, SaaS, analytics and AI-driven offerings.

Barrick (NYSE:B) will release its full year and fourth quarter 2025 results before markets open on Thursday, February 5, 2026 at 6:00 AM ET. Management will host a live webcast and presentation the same day at 11:00 AM ET followed by a question-and-answer session with analysts.

Presentation materials will be posted on the company website prior to the event and a replay will be available after the webcast. Registration is required to join the live webcast.

Hexagon Robotics (NYSE:B) announced a strategic partnership with Microsoft on January 7, 2026 to advance production-ready humanoid robots for manipulation and inspection use cases.

The collaboration will combine Hexagon's sensor fusion, robotics, and spatial intelligence with Microsoft's cloud and AI platforms including Azure, Microsoft Fabric Real-Time Intelligence, Azure IoT Operations, and Azure App Service. Initial industry targets are automotive, aerospace, manufacturing, and logistics.

Planned focus areas include:

• scaling physical AI frameworks (imitation learning, reinforcement learning, multimodal vision-language-action)
• data management and one-shot imitation learning
• joint customer deployments to move automation from concept to factory floor

Kennametal (NYSE: KMT) announced a new integration with Hexagon's cloud-based Tool Library to deliver verified Kennametal digital tooling data directly into Hexagon's WORKNC CAM software. The integration enables machinists to import realistic 3D models, smart assemblies and scalable tool data to reduce setup time and improve machining accuracy.

Initial support includes solid carbide drills and end mills for WORKNC users, with expansion to additional CAM systems and product lines planned in the coming months. The companies say the collaboration aims to accelerate digitalization of the manufacturing value chain and make validated tooling data more accessible to machine shops worldwide.

Cereno Scientific (Nasdaq First North: B) will attend JPM Week 2026 in San Francisco and participate at the Biotech Showcase from January 12–18, 2026, with Biotech Showcase sessions running January 12–14, 2026.

The company said it will hold investor and partner meetings throughout the week to discuss progress across its HDAC inhibitor portfolio, including advancement of lead candidate CS1 toward a global Phase IIb trial in PAH and Phase I data supporting CS014 moving into Phase II. Investors can request meetings via the Biotech Showcase partnering platform or by emailing business.development@cerenoscientific.com. For IR contact, use tove.bergenholt@cerenoscientific.com or phone +46 73-236 62 46.

ETQ (NYSE:B) was ranked a Front Runner in the Enterprise Quality Management Software Solution Selection Matrix 2025 by LNS Research on Dec 11, 2025. Out of 16 vendors evaluated, ETQ was one of three Front Runners.

LNS cited ETQ Reliance's extensive configurability, a unified workflow engine, strong customer support described as "agile and focused on customer success," and a broad application library. The report highlighted partnerships with Augmentir for frontline integration and Acerta for predictive quality analytics. LNS scored ETQ across Product, Potential, and Presence in its 3P model.

BioArctic (Nasdaq: B) partner Eisai announced that Leqembi (lecanemab) has been included in China’s new Commercial Insurance Innovative Drug List, effective January 1, 2026. The list enables commercial insurers to negotiate coverage products for listed innovative medicines, aiming to narrow the gap with the National Reimbursement Drug List.

Eisai launched Leqembi in China in June 2024 and estimates 17 million people had MCI or mild dementia due to Alzheimer’s in China in 2024. Leqembi was originally developed by BioArctic and is commercialized in China by Eisai; BioArctic retains Nordic commercialization rights and is preparing joint commercialization with Eisai in that region.